To evaluate the efficacy and safety of Chinese herbal compound-Qiangxinning Decoction in the treatment of chronic heart failure(CRF, non reserved)by evidence-based medicine.Methods:Chinese databases CNKI database, Wanfang database, VIP database and Sinomed database, as well as English databases PubMed, Medline databases and Corchrane Library were systematically retrieved.The period of literature retrieval was “not limited to March 2018”.“强心宁” and “Qiangxing” were used as keywords in full-text retrieval of Chinese and English databases.RCT literatures of Qiangxinning Decoction plus standard treatment control and standard treatment for CRF were included.The bias was evaluated with Corchrane Handbook, and Review Manage 5.3 was used to perform Meta-analysis on the measurement data.Sensitivity analysis was used to analyze the heterogeneity, and a reasonable explanation was made.The publication bias was evaluated by the inverted funnel plot.Results:A total of 752 patients were included in 10 RCT studies.The quality risk assessment was generally “unclear risk of bias”.The experimental group was compared with the control group, and the efficacy results showed that the effective rate：RD(95% CI)was 2.5 [0.82-8.39], and the heterogeneity was “P=0.95”; the left ventricular ejection fraction(LVEF)：MD(95% CI)was 0.60 [0.35-0.85], and the heterogeneity was “P=0.19”; the left ventricular end-diastolic diameter(LVEDD)：MD(95% CI)was-0.48 [-0.78 to-0.17], and the heterogeneity was “P=0.21”.Conclusion:Qiangxinning Decoction can relieve the clinical symptoms of heart failure patients with decreased ejection fraction, improve the ejection fraction to a certain extent, and reduce the left ventricular end-diastolic diameter, with less adverse reactions.However, the efficacy and safety still need strong evidence-based study to be further confirmed.